



# Recombinant Protein Technical Manual

## Recombinant Mouse PLAUR/uPAR Protein (His & Fc Tag)(Active)

RPES3571

### Product Data:

**Product SKU:** RPES3571

**Size:** 100µg

**Species:** Mouse

**Expression host:** HEK293 Cells

**Uniprot:** NP\_035243.1

### Protein Information:

**Molecular Mass:** 58 kDa

**AP Molecular Mass:** 80-90 kDa

**Tag:** C-His-Fc

**Bio-activity:** Measured by its binding ability in a functional ELISA. Immobilized human uPA at 5 µg/ml (100 µl/well) can bind mouse PLAUR with a linear rangel of 1.6-40 ng/ml.

**Purity:** > 97 % as determined by SDS-PAGE

**Endotoxin:** < 1.0 EU per µg of the protein as determined by the LAL method.

**Storage:** Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

**Shipping:** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation:** Lyophilized from sterile PBS, pH 7.4

**Reconstitution:** Please refer to the printed manual for detailed information.

**Application:** Functional ELISA

**Synonyms:** Cd87;u-PAR;uPAR

## Immunogen Information:

**Sequence:** Met 1-Thr 297

## Background:

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.